Small molecule · Inhibitor of thrombin (F2), plasmin (PLG) and kallikrein (KLK1) · developed by Ensysce Biosciences
Nafamostat is a broad-spectrum synthetic serine protease inhibitor with anticoagulant, anti-inflammatory, and potential antiviral activities. It inhibits multiple proteases including thrombin, plasmin, kallikrein, trypsin, and TMPRSS2, blocking trypsinogen activation in pancreatitis and potentially inhibiting viral cell entry. It is studied in healthy volunteers for pharmacokinetics and has potential applications in cystic fibrosis and viral infections.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06500793 | Phase 1 | Pharmacokinetics | Recruiting | ENSC |
| NCT04406415 | Phase 1 | Pharmacokinetics | Completed | ENSC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy VolunteerPharmacokinetics
Updated Oct 3, 2026. Something wrong or missing? Report it on the ENSC page.
See ENSC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ENSC catalysts and pipeline →